4 mos vs. 6 probably gains 90% of value (made up estimate) but it will be more than 66% - so agree with Dr. Roach. And I think you have a great point - better recovery could argue for more use. But that approach is more expensive: I don't track this stuff but a 2021 study was 27k vs 2.9k - more than cost of IMRT + brachy or protons under Medicare - so it better be good.
Nice essay. As a brachytherapist I was hoping to see more patients on the trial getting brachy boost so the question of dose could be better answered.
Mack Roach says 4 mo ADT is plenty. With relugolix and quick T recovery, could that confer some absolute benefit with less toxicity?
4 mos vs. 6 probably gains 90% of value (made up estimate) but it will be more than 66% - so agree with Dr. Roach. And I think you have a great point - better recovery could argue for more use. But that approach is more expensive: I don't track this stuff but a 2021 study was 27k vs 2.9k - more than cost of IMRT + brachy or protons under Medicare - so it better be good.
Thanks for reading and stopping by.